Safety and immunogenicity of a highly attenuated rVSVN4CT1-EBOVGP1 Ebola virus vaccine: a randomised,double-blind,placebo-controlled,phase 1 clinical trial |
| |
| Affiliation: | 1. Department of Virology and Vaccine Development, Profectus BioSciences, Pearl River, NY, USA;2. Department of Immunology, Profectus BioSciences, Pearl River, NY, USA;3. Department of Quality Assurance, Profectus BioSciences, Pearl River, NY, USA;4. Department of Regulatory Affairs, Profectus BioSciences, Pearl River, NY, USA;5. Bill and Melinda Gates Medical Research Institute, Cambridge, MA, USA;6. Joint Project Manager for Chemical, Biological, Radiological and Nuclear Medical, Fort Detrick, MD, USA |
| |
| Abstract: | |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
